Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10517507 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jun, 2032
(9 years from now) |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9393318 | ABRAXIS BIOSCIENCE | Methods of treating cancer |
Mar, 2032
(9 years from now) | |
US9597409 | ABRAXIS BIOSCIENCE | Methods of treating cancer |
Mar, 2032
(9 years from now) | |
US9393318
(Pediatric) | ABRAXIS BIOSCIENCE | Methods of treating cancer |
Sep, 2032
(9 years from now) | |
US9597409
(Pediatric) | ABRAXIS BIOSCIENCE | Methods of treating cancer |
Sep, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Dec 6, 2022 |
Pediatric Exclusivity (PED) | Jun 6, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of lung cancer
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8722738 | CUMBERLAND PHARMS | Acetycysteine compositions and methods of use thereof |
Apr, 2032
(9 years from now) |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 23 January, 2004
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions
Dosage: INJECTABLE;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9265737 | NEOS THERAPS INC | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles |
Jun, 2032
(9 years from now) | |
US9017731 | NEOS THERAPS INC | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(9 years from now) | |
US8709491 | NEOS THERAPS INC | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(9 years from now) |
Drugs and Companies using AMPHETAMINE ingredient
Market Authorisation Date: 15 September, 2017
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9017731 | NEOS THERAPS | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(9 years from now) | |
US9265737 | NEOS THERAPS | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles |
Jun, 2032
(9 years from now) | |
US8709491 | NEOS THERAPS | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(9 years from now) |
Drugs and Companies using AMPHETAMINE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(8 years from now) | |
US8978966 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(8 years from now) | |
US8714149 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2032
(9 years from now) | |
US10561808
(Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jul, 2032
(9 years from now) | |
US8978966
(Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jul, 2032
(9 years from now) | |
US8714149
(Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11312698 | HELSINN HLTHCARE | Fosnetupitant chloride hydrochloride having improved stability |
May, 2032
(9 years from now) | |
US10717721 | HELSINN HLTHCARE | Substituted piperaziniums for the treatment of emesis |
May, 2032
(9 years from now) | |
US8426450 | HELSINN HLTHCARE | Substituted 4-phenyl pyridines having anti-emetic effect |
May, 2032
(9 years from now) | |
US9908907 | HELSINN HLTHCARE | Substituted piperaziniums for the treatment of emesis |
May, 2032
(9 years from now) | |
US9403772 | HELSINN HLTHCARE | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
May, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8895586 | HELSINN HLTHCARE | Methods of treating emesis |
May, 2032
(9 years from now) | |
US10208073 | HELSINN HLTHCARE | Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator |
May, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 19, 2023 |
NCE-1 date: April, 2022
Market Authorisation Date: 19 April, 2018
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9365514 | HOFFMANN-LA ROCHE | Composition comprising tetracyclic compound |
Mar, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 6, 2024 |
Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 11 December, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10383876 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Mar, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9636344 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts |
Mar, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 14, 2022 |
Orphan Drug Exclusivity (ODE) | Sep 14, 2024 |
Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient
NCE-1 date: September, 2021
Market Authorisation Date: 14 September, 2017
Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9717740 | ETON | Treatment of adrenal insufficiency |
Nov, 2032
(9 years from now) |
Drugs and Companies using HYDROCORTISONE ingredient
Market Authorisation Date: 29 September, 2020
Treatment: Treatment of adrenal insufficiency
Dosage: GRANULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10570391 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(9 years from now) | |
US9399775 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 13, 2027 |
Drugs and Companies using VUTRISIRAN ingredient
NCE-1 date: June, 2026
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9750747 | SUNOVION PHARMS INC | Treatments involving eslicarbazepine acetate or eslicarbazepine |
Aug, 2032
(9 years from now) |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
Market Authorisation Date: 08 November, 2013
Treatment: Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; Treatment of partial-onset seizures
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10226458 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Mar, 2032
(9 years from now) | |
US9034867 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Nov, 2032
(9 years from now) |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(8 years from now) | |
US8978966 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(8 years from now) | |
US8714149 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2032
(9 years from now) | |
US10561808
(Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jul, 2032
(9 years from now) | |
US8978966
(Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jul, 2032
(9 years from now) | |
US8714149
(Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 9, 2024 |
New Strength (NS) | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9284314 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
US9695122 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
US8969566 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 25, 2020 |
Generating Antibiotic Incentives Now (GAIN) | Feb 25, 2025 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: February, 2024
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9079928 | COMMAVE THERAP | Methylphenidate-oxoacid conjugates, processes of making and using the same |
Jul, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 7, 2026 |
NCE-1 date: May, 2025
Market Authorisation Date: 07 May, 2021
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9901539 | BDSI | Transmucosal drug delivery devices for use in chronic pain relief |
Dec, 2032
(9 years from now) |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 October, 2015
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: FILM;BUCCAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8633178 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US8993549 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US10052386 | THERAPEUTICSMD INC | Progesterone formulations |
Nov, 2032
(9 years from now) | |
US8987237 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US11166963 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US8933059 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US11103513 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US10806740 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US9006222 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US11033626 | THERAPEUTICSMD INC | Progesterone formulations having a desirable pk profile |
Nov, 2032
(9 years from now) | |
US10675288 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US9114145 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US9114146 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US8846648 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US8846649 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US10206932 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US11103516 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US8993548 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US11110099 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
US10639375 | THERAPEUTICSMD INC | Progesterone formulations |
Nov, 2032
(9 years from now) | |
US9301920 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) |
Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient
Market Authorisation Date: 28 October, 2018
Treatment: Treatment of menopause symptoms, including vasomotor symptoms
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11529360 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) |
Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient
Market Authorisation Date: 28 October, 2018
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 18, 2026 |
New Chemical Entity Exclusivity (NCE) | Feb 7, 2023 |
New Patient Population (NPP) | Jun 18, 2022 |
M | Feb 24, 2024 |
NCE-1 date: February, 2022
Market Authorisation Date: 07 February, 2018
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8962572 | FRESENIUS KABI USA | Bortezomib formulations |
Nov, 2032
(9 years from now) |
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 06 November, 2017
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9387208 | ARRAY BIOPHARMA INC | Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(9 years from now) | |
US10258622 | ARRAY BIOPHARMA INC | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate |
Nov, 2032
(9 years from now) | |
US9763941 | ARRAY BIOPHARMA INC | Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 27, 2023 |
Orphan Drug Exclusivity (ODE) | Jun 27, 2025 |
New Indication (I) | Apr 8, 2023 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; Treatment of melanoma
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8703177 | BDSI | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
Aug, 2032
(9 years from now) |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: NA
Dosage: FILM;BUCCAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11298349 | EXELIXIS INC | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 17, 2028 |
New Indication (I) | Sep 17, 2024 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9072710 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(9 years from now) | |
US9072661 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Nov 19, 2024 |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 11 June, 2009
Treatment: Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) | |
CN106243113B | ASTRAZENECA | As A Selective Btk Inhibitor And Pyrazine |
Jul, 2032
(9 years from now) | |
CN103889987A | ASTRAZENECA | As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide |
Jul, 2032
(9 years from now) | |
CN106243113A | ASTRAZENECA | Imidazole As Selective Btk Inhibitors And Paradiazine |
Jul, 2032
(9 years from now) | |
CN103889987B | ASTRAZENECA | Imidazole As Selective Btk Inhibitors And Paradiazine |
Jul, 2032
(9 years from now) | |
EP3689878B1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
EP3689878A1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
EP2734522B1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
EP2734522A1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) | |
US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 21, 2026 |
New Chemical Entity Exclusivity (NCE) | Oct 31, 2022 |
New Indication (I) | Nov 21, 2022 |
Drugs and Companies using ACALABRUTINIB ingredient
NCE-1 date: October, 2021
Market Authorisation Date: 31 October, 2017
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) | |
CN106243113B | ASTRAZENECA | As A Selective Btk Inhibitor And Pyrazine |
Jul, 2032
(9 years from now) | |
CN103889987A | ASTRAZENECA | As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide |
Jul, 2032
(9 years from now) | |
CN106243113A | ASTRAZENECA | Imidazole As Selective Btk Inhibitors And Paradiazine |
Jul, 2032
(9 years from now) | |
CN103889987B | ASTRAZENECA | Imidazole As Selective Btk Inhibitors And Paradiazine |
Jul, 2032
(9 years from now) | |
EP3689878B1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
EP3689878A1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
EP2734522B1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
EP2734522A1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(9 years from now) | |
US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: October, 2021
Market Authorisation Date: 03 August, 2022
Treatment: Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9636407 | FRESENIUS KABI USA | Caspofungin acetate formulations |
Dec, 2032
(9 years from now) |
Drugs and Companies using CASPOFUNGIN ACETATE ingredient
Market Authorisation Date: 30 December, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8747894 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(9 years from now) | |
US9561204 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(9 years from now) | |
US9427421 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(9 years from now) |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 29 January, 2016
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions
Dosage: TABLET, EFFERVESCENT;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11298349 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(9 years from now) | |
US9717720 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(9 years from now) |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Market Authorisation Date: 29 November, 2012
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9248123 | NALPROPION | Methods of providing weight loss therapy in patients with major depression |
Jan, 2032
(8 years from now) |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE46621 | SECURA | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
May, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11312718 | SECURA | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
Jan, 2032
(8 years from now) | |
US9840505 | SECURA | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
Jan, 2032
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 24, 2023 |
Orphan Drug Exclusivity (ODE) | Sep 24, 2025 |
Drugs and Companies using DUVELISIB ingredient
NCE-1 date: September, 2022
Market Authorisation Date: 24 September, 2018
Treatment: For the treatment of patients with follicular lymphoma (fl); For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9089496 | NEOS THERAPS INC | Compositions comprising methylphenidate complexed with ion-exchange resin particles |
Jun, 2032
(9 years from now) | |
US9072680 | NEOS THERAPS INC | Compositions comprising methylphenidate complexed with ion-exchange resin particles |
Jun, 2032
(9 years from now) |
Drugs and Companies using METHYLPHENIDATE ingredient
Market Authorisation Date: 19 June, 2017
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11000522 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(9 years from now) | |
US8431155 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(9 years from now) | |
US9700555 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(9 years from now) | |
US9993474 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(9 years from now) | |
US9192576 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(9 years from now) | |
US8613947 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(9 years from now) | |
US9522117 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(9 years from now) | |
US10688094 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(9 years from now) |
Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient
Market Authorisation Date: 05 May, 2009
Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 11; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 13 and 23; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1, 11, and 12; Adjunct to diet exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 13, 23, and 24; Improvement of glycemic control in individuals with type 2 diabetes; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 41, 52, and 53; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 66, 75, and 76; Adjunct to diet and execrise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 29, 39, and 40; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1, 13, and 14; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 54 and 64; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 29 and 39; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 13; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 66 and 75; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 41 and 52; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 89, 99, and 100; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 54, 64, and 65; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 15, 27, and 28; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 15 and 27; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 77 and 87; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 89 and 99; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 77, 87, and 88; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 43, 50 and 51; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 1,10 and 11; Adjunct to diet and excercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 30, 41, and 42; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 1 and 10; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 30 and 41; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 21 and 28; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 12 and 19; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 43 and 50; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 12, 19 and 20; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 21, 28, and 29; Administration once daily within two hours after waking in the morning for improvement of glycemic control in a type 2 diabetes patient; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 2 and 3; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 4 and 5; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 7, 8, and 9; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 2; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 4, 5, and 6; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 7 and 8; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 10 and 11; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 16, 17, and 18; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 13 and 14; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 10, 11, and 12; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 16 and 17; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 13, 14, and 15; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 28 and 29; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 25 and 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 22, 23, and 24; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 19 and 20; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 19, 20, and 21; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 28, 29, and 30; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 25, 26, and 27
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11085043 | JAZZ PHARMS INC | Euglobulin-based method for determining the biological activity of defibrotide |
Jun, 2032
(9 years from now) | |
US11236328 | JAZZ PHARMS INC | Euglobulin-based method for determining the biological activity of defibrotide |
Jun, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Mar 30, 2023 |
Drugs and Companies using DEFIBROTIDE SODIUM ingredient
Market Authorisation Date: 30 March, 2016
Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (hsct)
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 28, 2024 |
New Indication (I) | Oct 3, 2022 |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
Market Authorisation Date: 04 April, 2016
Treatment: Prophylaxis of hiv-1 infection; Treatment of hiv-1 infection; Treatment of hiv infection
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10159759 | RADIOMEDIX | Pet tracer for imaging of neuroendocrine tumors |
Aug, 2032
(9 years from now) | |
US10383961 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(9 years from now) | |
US11160888 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 3, 2025 |
Orphan Drug Exclusivity (ODE) | Sep 3, 2027 |
Drugs and Companies using COPPER DOTATATE CU-64 ingredient
NCE-1 date: September, 2024
Market Authorisation Date: 03 September, 2020
Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9233103 | TAKEDA PHARMS USA | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
Mar, 2032
(9 years from now) |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10799642 | EYEPOINT PHARMS | Dose guides for injection syringe |
May, 2032
(9 years from now) |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 09 February, 2018
Treatment: NA
Dosage: SUSPENSION;INTRAOCULAR
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9731082 | FRESENIUS KABI USA | Drug container |
Apr, 2032
(9 years from now) |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 January, 1984
Treatment: NA
Dosage: INJECTABLE;INJECTION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8546436 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Feb, 2032
(9 years from now) |
Drugs and Companies using ALLOPURINOL; LESINURAD ingredient
Market Authorisation Date: 18 August, 2017
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9855214 | SILVERGATE PHARMS | Enalapril compositions |
Nov, 2032
(9 years from now) | |
US9968553 | SILVERGATE PHARMS | Enalapril compositions |
Nov, 2032
(9 years from now) | |
US8778366 | SILVERGATE PHARMS | Enalapril compositions |
Nov, 2032
(9 years from now) | |
US8568747 | SILVERGATE PHARMS | Enalapril compositions |
Nov, 2032
(9 years from now) |
Drugs and Companies using ENALAPRIL MALEATE ingredient
Market Authorisation Date: 13 August, 2013
Treatment: Method of treatment of heart failure; Treatment of hypertension; Method of treating left ventricular dysfunction; Method of treating hypertension; Treatment of heart failure
Dosage: FOR SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
M | Apr 27, 2025 |
Pediatric Exclusivity (PED) | Dec 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
Market Authorisation Date: 10 June, 2021
Treatment: For the treatment of hepatitis c
Dosage: PELLETS;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9687465 | GALDERMA LABS LP | Compositions for the treatment of rosacea |
Nov, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Apr 22, 2025 |
Drugs and Companies using BENZOYL PEROXIDE ingredient
Market Authorisation Date: 22 April, 2022
Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older
Dosage: CREAM;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10039718 | BRISTOL-MYERS SQUIBB | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) |
Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient
Market Authorisation Date: 29 January, 2015
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8627816 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2032
(9 years from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8627816 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2032
(9 years from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8865937 | ALLERGAN | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide |
May, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Oct 7, 2022 |
Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient
Market Authorisation Date: 25 July, 2013
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11268128 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(9 years from now) | |
US11274332 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(9 years from now) | |
US11274331 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(9 years from now) | |
US11060128 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 28, 2023 |
Orphan Drug Exclusivity (ODE) | Nov 28, 2025 |
New Patient Population (NPP) | Sep 29, 2025 |
Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient
NCE-1 date: November, 2022
Market Authorisation Date: 28 November, 2018
Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9415085 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(9 years from now) | |
US10695398 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(9 years from now) |
Drugs and Companies using DEGARELIX ACETATE ingredient
Market Authorisation Date: 24 December, 2008
Treatment: Method of treating prostate cancer
Dosage: POWDER;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) |
Market Authorisation Date: 05 November, 2015
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9592208 | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Mar, 2032
(9 years from now) | |
US9592208
(Pediatric) | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Sep, 2032
(9 years from now) |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
Market Authorisation Date: 21 September, 2010
Treatment: Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9101592 | POHL BOSKAMP | Stabilized granules containing glyceryl trinitrate |
Mar, 2032
(9 years from now) |
Drugs and Companies using NITROGLYCERIN ingredient
Market Authorisation Date: 08 June, 2016
Treatment: NA
Dosage: POWDER;SUBLINGUAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9393256 | GILEAD SCIENCES INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
US10456414 | GILEAD SCIENCES INC | Methods for treating HCV |
Sep, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Dosing Schedule (D) | Nov 15, 2022 |
Orphan Drug Exclusivity (ODE) | Apr 7, 2024 |
Pediatric Exclusivity (PED) | Oct 7, 2024 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
Market Authorisation Date: 10 October, 2014
Treatment: For the treatment of hepatitis c
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8921337 | NOVARTIS | Carboxyvinyl polymer-containing nanoparticle suspensions |
Mar, 2032
(9 years from now) |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 16 October, 2012
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10537581 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11246875 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11241445 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US10835487 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US9289382 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US10806697 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11351182 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11304959 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11497709 | THERAPEUTICSMD INC | NA |
Nov, 2032
(9 years from now) |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 May, 2018
Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy
Dosage: INSERT;VAGINAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8945612 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(9 years from now) | |
US8685442 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(9 years from now) | |
US8545878 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(9 years from now) | |
US9393210 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(9 years from now) |
Drugs and Companies using LEVODOPA ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10391094 | IMPACT | Compositions and methods for treating myelofibrosis |
Jun, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Aug 16, 2026 |
New Chemical Entity Exclusivity (NCE) | Aug 16, 2024 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8781571 | THE MEDICINES CO | Switch validation circuit and method |
Mar, 2032
(9 years from now) | |
US8428708 | THE MEDICINES CO | Self-test for analgesic product |
May, 2032
(9 years from now) | |
US8428709 | THE MEDICINES CO | Current control for electrotransport drug delivery |
Jun, 2032
(9 years from now) |
Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 May, 2006
Treatment: Method for iontophoretic transdermal delivery of fentanyl hydrochloride
Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10772888 | MERCK SHARP DOHME | Solid pharmaceutical compositions containing an integrase inhibitor |
Mar, 2032
(9 years from now) |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 12 October, 2007
Treatment: Treatment of hiv-1 infection
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11241392 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US10905652 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US10182995 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US8927010 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US9023389 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US9283214 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US9498447 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US11241391 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US10881618 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US10617651 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US10292937 | IRONSHORE PHARMS | Methods of treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US9603809 | IRONSHORE PHARMS | Methods of treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US8916588 | IRONSHORE PHARMS | Methods for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US9034902 | IRONSHORE PHARMS | Methods for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
US9028868 | IRONSHORE PHARMS | Methods and compositions for treatment of attention deficit disorder |
Mar, 2032
(9 years from now) |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 August, 2018
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10842801 | CORCEPT THERAP | Optimizing mifepristone absorption |
Nov, 2032
(9 years from now) |
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9216178 | BIOMARIN PHARM | Dry blend formulation of tetrahydrobiopterin |
Nov, 2032
(9 years from now) |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2013
Treatment: NA
Dosage: POWDER;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9731869 | BTCP PHARMA | Container |
Jan, 2032
(8 years from now) |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 30 June, 2011
Treatment: NA
Dosage: SPRAY, METERED;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9168238 | FRESENIUS KABI USA | Levothyroxine formulations |
Aug, 2032
(9 years from now) | |
US9168239 | FRESENIUS KABI USA | Levothyroxine formulations |
Aug, 2032
(9 years from now) | |
US9006289 | FRESENIUS KABI USA | Levothyroxine formulations |
Oct, 2032
(9 years from now) |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 24 June, 2011
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11376251 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 29, 2026 |
Orphan Drug Exclusivity (ODE) | Sep 29, 2028 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: September, 2025
Market Authorisation Date: 29 September, 2021
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11406662 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(9 years from now) | |
US10413569 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(9 years from now) | |
US8802152 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Apr, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8808750 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(9 years from now) | |
US9844567 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(9 years from now) | |
US9861658 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(9 years from now) | |
US10335432 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(9 years from now) | |
US10398730 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 18, 2023 |
M | Apr 24, 2023 |
Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient
NCE-1 date: May, 2022
Market Authorisation Date: 18 May, 2018
Treatment: Treatment of hyperkalemia in adults
Dosage: FOR SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9168556 | SUNOVION RESP | Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer |
Sep, 2032
(9 years from now) |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8778960 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Feb, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 28, 2026 |
Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient
NCE-1 date: May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8648037 | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jan, 2032
(8 years from now) | |
US8937150 | ABBVIE INC | Anti-viral compounds |
May, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8648037
(Pediatric) | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jul, 2032
(9 years from now) | |
US8937150
(Pediatric) | ABBVIE INC | Anti-viral compounds |
Nov, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 3, 2022 |
M | Apr 10, 2023 |
New Dosing Schedule (D) | Sep 26, 2022 |
Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
Pediatric Exclusivity (PED) | Mar 26, 2023 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: March, 2022
Market Authorisation Date: 10 June, 2021
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg
Dosage: PELLETS;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9399021 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
US9271941 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
US9155706 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
US8580304 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 22, 2024 |
M | Oct 6, 2022 |
New Indication (I) | Jun 22, 2025 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
Market Authorisation Date: 29 May, 2013
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9012469 | REDHILL | Crystalline naloxol-peg conjugate |
Apr, 2032
(9 years from now) |
Drugs and Companies using NALOXEGOL OXALATE ingredient
Market Authorisation Date: 16 September, 2014
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8415337 | RECORDATI RARE | Ibuprofen compositions and methods of making same |
Mar, 2032
(9 years from now) |
Drugs and Companies using IBUPROFEN LYSINE ingredient
Market Authorisation Date: 13 April, 2006
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9375498 | AAA USA INC | Process for the preparation of complexes of 68Ga |
Aug, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 1, 2023 |
Drugs and Companies using GALLIUM DOTATATE GA-68 ingredient
Market Authorisation Date: 01 June, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9925150 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Mar, 2032
(9 years from now) |
Drugs and Companies using ROTIGOTINE ingredient
Market Authorisation Date: 09 May, 2007
Treatment: NA
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9198858 | CHEMO RESEARCH SL | Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations |
Jun, 2032
(9 years from now) | |
US8946276 | CHEMO RESEARCH SL | High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis |
Jun, 2032
(9 years from now) | |
US10596155 | CHEMO RESEARCH SL | Aqueous-based metronidazole gel formulations |
Jun, 2032
(9 years from now) | |
US10238634 | CHEMO RESEARCH SL | Aqueous-based metronidazole gel formulations |
Jun, 2032
(9 years from now) |
Drugs and Companies using METRONIDAZOLE ingredient
Market Authorisation Date: 24 March, 2014
Treatment: Treatment of bacterial vaginosis with metronidazole gel
Dosage: GEL;VAGINAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) |
Market Authorisation Date: 01 March, 2016
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9399012
(Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Mar, 2032
(9 years from now) |
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 02 November, 2010
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11077098 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(9 years from now) | |
US9309234 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(9 years from now) | |
US8835488 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9642842 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 30, 2025 |
Drugs and Companies using OLICERIDINE ingredient
NCE-1 date: October, 2024
Market Authorisation Date: 30 October, 2020
Treatment: Management of acute pain by intravenous injection
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9089574 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
Nov, 2032
(9 years from now) | |
US11045474 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections |
Nov, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | May 10, 2025 |
New Chemical Entity Exclusivity (NCE) | May 31, 2023 |
Drugs and Companies using BARICITINIB ingredient
NCE-1 date: May, 2022
Market Authorisation Date: 31 May, 2018
Treatment: Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo)
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9630955 | NEUROCRINE | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor |
Dec, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: April, 2024
Market Authorisation Date: 24 April, 2020
Treatment: Method of treating parkinson's disease
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10034879 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Dec, 2032
(9 years from now) | |
US10806733 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Dec, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10017491 | GLOBAL BLOOD THERAPS | Compounds and uses thereof for the modulation of hemoglobin |
Dec, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 25, 2024 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: November, 2023
Market Authorisation Date: 17 December, 2021
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Jan 16, 2023 |
New Chemical Entity Exclusivity (NCE) | Dec 5, 2022 |
New Dosing Schedule (D) | Mar 28, 2025 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8791154 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(9 years from now) | |
US9533053 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(9 years from now) |
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 2015
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10285946 | ONCOPEPTIDES AB | Lyophilized preparations of melphalan flufenamide |
Apr, 2032
(9 years from now) | |
US11344622 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(9 years from now) | |
US10543274 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(9 years from now) | |
US10322182 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(9 years from now) | |
US10869928 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Feb 26, 2028 |
New Chemical Entity Exclusivity (NCE) | Feb 26, 2026 |
Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient
NCE-1 date: February, 2025
Market Authorisation Date: 26 February, 2021
Treatment: In combination with dexamethasone to treat relapsed or refactory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received at least 4 prior lines of therapy
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11529368 | SALIX | Colonoscopy—preparation |
Mar, 2032
(9 years from now) | |
US10780112 | SALIX | Colonoscopy-preparation |
Mar, 2032
(9 years from now) | |
US10792306 | SALIX | Colonoscopy—preparation |
Mar, 2032
(9 years from now) | |
US10646512 | SALIX | Colonoscopy - preparation |
Mar, 2032
(9 years from now) | |
US9592252 | SALIX | Colonoscopy—preparation |
Aug, 2032
(9 years from now) |
Market Authorisation Date: 04 May, 2018
Treatment: For cleansing of the colon in preparation for colonoscopy in adults
Dosage: FOR SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9062014 | JANSSEN PHARMS | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
May, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8338470 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US8455527 | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US8648106 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US9616049 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US8242158 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US10016396 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US9320712 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
US8455527
(Pediatric) | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
US8338470
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
US9320712
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
US9616049
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
US8242158
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
US8648106
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 December, 1999
Treatment: Use for sedation
Dosage: INJECTABLE;INJECTION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) |
Drugs and Companies using COBICISTAT; DARUNAVIR ingredient
Market Authorisation Date: 29 January, 2015
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(8 years from now) | |
US8978966 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(8 years from now) |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 31 March, 2015
Treatment: NA
Dosage: POWDER, METERED;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(8 years from now) |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 29 October, 2004
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10085958 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2032
(9 years from now) |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 05 April, 2013
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9682080 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(9 years from now) | |
US10632114 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(9 years from now) | |
US9980961 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(9 years from now) | |
US9193701 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
Oct, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 17, 2027 |
Drugs and Companies using MITAPIVAT SULFATE ingredient
NCE-1 date: February, 2026
Market Authorisation Date: 17 February, 2022
Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8461179 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE48731 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 15, 2025 |
Orphan Drug Exclusivity (ODE) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: Treatment of gastrointestinal stromal tumor
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8754096 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of episodic migraine in adults
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(8 years from now) |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 15 September, 2000
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10561808 | NORTON WATERFORD | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(8 years from now) |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9326966 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(9 years from now) | |
US8404215 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging |
Mar, 2032
(9 years from now) | |
US9095559 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(9 years from now) | |
US9254278 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 28, 2024 |
Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient
Market Authorisation Date: 01 February, 2013
Treatment: Treatment of a urea cycle disorder; Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder
Dosage: LIQUID;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8561859 | ALLERGAN | Dispensing device |
Apr, 2032
(9 years from now) |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: NA
Dosage: EMULSION;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10307419 | OTSUKA | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
Oct, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Dec 27, 2024 |
Drugs and Companies using BREXPIPRAZOLE ingredient
Market Authorisation Date: 10 July, 2015
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(9 years from now) | |
US9132239
(Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Dec 4, 2023 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 23 December, 2014
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8763222 | INTERSECT ENT INC | Methods and devices for crimping self-expanding devices |
Feb, 2032
(9 years from now) |
Drugs and Companies using MOMETASONE FUROATE ingredient
Market Authorisation Date: 08 December, 2017
Treatment: NA
Dosage: IMPLANT;IMPLANTATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9957232 | BAYER HLTHCARE | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate |
Jul, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 27, 2024 |
Drugs and Companies using REGORAFENIB ingredient
Market Authorisation Date: 27 September, 2012
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) |
Market Authorisation Date: 27 August, 2012
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8921387 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jan, 2032
(8 years from now) |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 30 November, 2017
Treatment: Treating opioid dependency by administering buprenorphine once per month; Treating opioid dependence by administering buprenorphine
Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8754065 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
US9296769 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) |
Market Authorisation Date: 17 July, 2018
Treatment: Treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months; Treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10596120 | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Mar, 2032
(9 years from now) |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 09 December, 2016
Treatment: Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin; Treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11524951 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(9 years from now) | |
US9732058 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(9 years from now) | |
US8946235 | ASTRAZENECA | 2-(2,4,5-substituted-anilino) pyrimidine compounds |
Aug, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 18, 2027 |
New Indication (I) | Dec 18, 2023 |
Drugs and Companies using OSIMERTINIB MESYLATE ingredient
Market Authorisation Date: 13 November, 2015
Treatment: Treatment of patients with metastatic epidermal growth factor receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy; Treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; Adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9061029 | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Apr, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9061029
(Pediatric) | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Oct, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 23, 2028 |
Pediatric Exclusivity (PED) | Sep 22, 2025 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 29 October, 2007
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml) by administering nilotinib dispersed in a fruit preparation
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8771648 | RIGEL PHARMS INC | (Trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(9 years from now) | |
US8951504 | RIGEL PHARMS INC | (trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 17, 2025 |
New Chemical Entity Exclusivity (NCE) | Apr 17, 2023 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: April, 2022
Market Authorisation Date: 17 April, 2018
Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11052093 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
US9090562 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9522152 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
US9855275 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
US8765732 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
US10155002 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
US9549931 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
US10420775 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 23, 2025 |
New Indication (I) | Jun 18, 2023 |
Orphan Drug Exclusivity (ODE) | Jan 23, 2027 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: January, 2024
Market Authorisation Date: 23 January, 2020
Treatment: Method of treating a lung metastasis of epithelioid sarcoma; Method of treating epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating relapsed or refractory follicular lymphoma; Method of treating follicular lymphoma
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(9 years from now) |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
Market Authorisation Date: 24 July, 2015
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8791097 | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
May, 2032
(9 years from now) | |
US8791097
(Pediatric) | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
Nov, 2032
(9 years from now) |
Drugs and Companies using TEMSIROLIMUS ingredient
Market Authorisation Date: 30 May, 2007
Treatment: Method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; Method of treating metastatic papillary renal cell carcinoma with temsirolimus.
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10596120 | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Mar, 2032
(9 years from now) |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: Treatment of a treatment-naive patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprisingmetformin and an outer coating comprising empagliflozin and linagliptin; Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin and linagliptin
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9278096 | TAKEDA PHARMS USA | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
Mar, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jan 22, 2024 |
Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient
Market Authorisation Date: 30 September, 2013
Treatment: Use in the treatment of major depressive disorder to improve treatment emergent sexual dysfunction (tesd) induced by prior serotonin reuptake inhibitor treatment
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9550036 | IMPEL NEUROPHARMA | Nasal drug delivery device |
Sep, 2032
(9 years from now) | |
US10507295 | IMPEL NEUROPHARMA | Nasal drug delivery device |
Dec, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Sep 2, 2024 |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Market Authorisation Date: 02 September, 2021
Treatment: NA
Dosage: SPRAY, METERED;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11319346 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Mar, 2032
(9 years from now) | |
US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: January, 2021
Market Authorisation Date: 19 January, 2017
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9457093 | SEAGEN | Solid dispersions of a ERB2 (HER2) inhibitor |
Oct, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 17, 2027 |
New Chemical Entity Exclusivity (NCE) | Apr 17, 2025 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9066942 | MAINPOINTE | Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer |
Jan, 2032
(8 years from now) | |
US9107921 | MAINPOINTE | Oral dosage forms for oxygen containing active agents and oxyl-containing polymers |
Jan, 2032
(8 years from now) |
Drugs and Companies using CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE ingredient
Market Authorisation Date: 22 June, 2015
Treatment: Treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Aug 22, 2026 |
New Patient Population (NPP) | Aug 22, 2022 |
Drugs and Companies using COBICISTAT ingredient
Market Authorisation Date: 24 September, 2014
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8754096 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with headache, with or without aura in adults
Dosage: TABLET;ORAL